Invasive breast cancers that are positive for the estrogen receptor and/or the progesterone receptor can be managed systemically with a variety of endocrine agents, such as tamoxifen for premenopausal patients and tamoxifen or one of the aromatase inhibitors for postmenopausal patients. The gene discussed is PGR; the disease is breast cancer.